EMA Acts To Freeze GVK Drugs, Guard Against Shortages
This article was originally published in PharmAsia News
Executive Summary
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.